Abstract: Slide Presentations |

Roflumilast Improves Lung Function and Quality of Life in Chronic Obstructive Pulmonary Disease FREE TO VIEW

Klaus F. Rabe, Prof.*; D. O’Donnell, MD; E.D. Bateman, MD; K. Andrae, MD; S. Witte, MD; D. Bredenbroeker, MD
Author and Funding Information

Leiden University Medical Center, RC Leiden, the Netherlands


Chest. 2004;126(4_MeetingAbstracts):709S. doi:10.1378/chest.126.4_MeetingAbstracts.709S-a
Text Size: A A A
Published online


PURPOSE:  Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory airway disease. To date, limited effective treatments are available that target the underlying disease pathophysiology of inflammation. Roflumilast is an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor with demonstrated anti-inflammatory activity. This study compared the efficacy of roflumilast 250 μg and 500 μg against placebo in patients with moderate-to-severe COPD.

METHODS:  This was a double-blind, randomized, placebo-controlled, multinational, multicenter study. After a 4-week run-in period, 1411 patients with forced expiratory volume in 1 second (FEV1) of 30% to 80% of predicted and post-salbutamol reversibility of < 12% and/or < 200 mL were treated with oral roflumilast 250 μg (N = 576) or 500 μg (N = 555), or placebo (N = 280) once daily for 24 weeks. Lung function and health-related quality of life were assessed by spirometry and the St. George’s Respiratory Questionnaire (SGRQ), respectively.

RESULTS:  After 24 weeks of treatment, post-salbutamol FEV1 increased from baseline with roflumilast 250 μg and 500 μg (29 mL and 51 mL, respectively; p < 0.0134). In contrast, the placebo group experienced a decline in FEV1 (-45 mL; p = 0.0041) as the disease progressed over the course of the investigation. At study end, differences in FEV1 between roflumilast 250 μg and 500 μg, and placebo were 74 mL and 97 mL, respectively (p<0.0001 for both doses). FEV6 also improved with roflumilast 250 μg and 500 μg (95 mL and 135 mL, respectively; p < 0.0001) as compared with placebo. Change in SGRQ total score was greater with roflumilast 250 μg and 500 μg (3.35 and 3.51 unit decrease, respectively) as compared with placebo (1.79 unit decrease).

CONCLUSION:  Oral, once-daily roflumilast significantly improved lung function and health-related quality of life in patients with moderate-to-severe COPD.

CLINICAL IMPLICATIONS:  Roflumilast, a new class of anti-inflammatory agent may prove useful in COPD therapy.

DISCLOSURE:  K.F. Rabe, None.

Monday, October 25, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543